Trial | NCT02390349  Report issue

Title

"CuraMed" and "Curamin" in Osteoarthritis

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    curcumin ...

  • Study Participants

    179
This randomized, placebo-controlled study evaluates the effects of CuraMed ® (BCM-95 ®) and Curamin ® in the treatment of osteoarthritis. One group will receive CuraMed, one group will receive Curamin and one group will receive placebo.
Study Started
Apr 30
2015
Primary Completion
May 31
2016
Study Completion
Dec 31
2016
Last Update
Jun 22
2017

Other Placebo

Dietary Supplement Curamin

Dietary Supplement CuraMed

CuraMed (BCM-95) Experimental

67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks

Curamin Experimental

67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks

Placebo Placebo Comparator

67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks

Criteria 

Inclusion Criteria:

Patients with a diagnosis of degenerative hypertrophic osteoarthritis of the knee (M17, according to International Classification of Diseases (ICD-10) of bone joints, verified by radiography (Grade 1-3 by Kellgren-Lawrence radiographic grades).

Exclusion Criteria:

subjects with inflammatory and any secondary arthritis
moderate and severe synovitis (grades 2 and 3)
tear of meniscus
chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems
allergic anamnesis and drug intolerance
pregnant or nursing
history of substance abuse
subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study
subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within three months prior to the study
No Results Posted